SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 1982; 43: 103108.
  • 2
    Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290296.
  • 3
    Feighner JP, Boyer WF. Serotonin-1A anxiolytics: An overview. Psychopathology 1989; 22 (Suppl. 1): 2126.
  • 4
    Nishitsuji K, To H, Murakami Y et al. Tandospirone in the treatment of generalized anxiety disorder and mixed anxiety-depression. Clin. Drug Invest. 2004; 24: 121126.
  • 5
    Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. 1997; 62: 348354.
  • 6
    Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Ther. 1998; 63: 640645.
  • 7
    Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 2005; 28: 17111716.
  • 8
    Natsui K, Mizuno Y, Tani N, Yabuki M, Komuro S. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 2007; 32: 233240.
  • 9
    Nishikawa H, Inoue T, Masui T, Izumi T, Koyama T. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 926931.
  • 10
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996; 51: 7378.
  • 11
    Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 1994; 46: 3539.
  • 12
    Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J. Clin. Pharmacol. 2003; 43: 12741282.
  • 13
    Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry 1993; 54: 269271.
  • 14
    Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J. Clin. Psychopharmacol. 1998; 18: 465469.
  • 15
    Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J. Clin. Psychiatry 2001; 62: 448452.
  • 16
    Anderson IM, Deakin JF, Miller HE. The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology (Berl) 1996; 128: 7482.
  • 17
    Lamberg TS, Kivisto KT, Laitila J, Martensson K, Neuvonen PJ. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur. J. Clin. Pharmacol. 1998; 54: 761766.
  • 18
    Fanselow MS. Conditioned and unconditional components of post-shock freezing. Pavlov. J. Biol. Sci. 1980; 15: 177182.
  • 19
    Ohmori T, Abekawa T, Muraki A, Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol. Biochem. Behav. 1994; 48: 587591.
  • 20
    Mochizuki D, Tsujita R, Yamada S et al. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 2002; 162: 323332.
  • 21
    Abe M, Nakai H, Tabata R, Saito K, Egawa M. Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn. J. Pharmacol. 1998; 76: 297304.
  • 22
    Nishikawa H, Inoue T, Izumi T, Koyama T. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats. Eur. Neuropsychopharmacol. 2007; 17: 643650.
  • 23
    Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114129.